Q-omics provides the consensus-scored IFNL1 profile across patient tissues and cancer cell-line models. IFNL1 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, IFNL1 is differentially expressed in 9, with the highest sampling consensus in HNSC. Additionally, IFNL1 RNA expression shows 8,965 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight UVM, HNSC, and TGCT as cancer lineages where IFNL1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for IFNL1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes IFNL1 survival associations across molecular data types. IFNL1 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible IFNL1 RNA expression–survival associations across cancer types. High IFNL1 expression shows unfavorable associations in UVM, COAD, UCEC and THYM, but favorable associations in SKCM and ESCA. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for IFNL1 RNA expression.
This table summarizes IFNL1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for IFNL1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. IFNL1 shows higher tumor expression in HNSC, BRCA, KIRC, BLCA, LUAD and LUSC. The HNSC box plot shows higher IFNL1 RNA expression in tumor versus normal tissue (log2 FC = +0.381, t-test p < 0.001).
This table shows molecular features associated with IFNL1 in patient tissues and cancer cell lines. In patient samples, IFNL1 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, IFNL1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in BREAST and BLOOD_Lymphoma.
